Literature DB >> 22987912

Ashwagandha root in the treatment of non-classical adrenal hyperplasia.

Amir Kalani1, Gul Bahtiyar, Alan Sacerdote.   

Abstract

Congenital adrenal hyperplasia (CAH) is a well-characterised family of disorders of the adrenal cortices, resulting in varying degrees of cortisol, aldosterone and androgen deficiency or androgen excess, depending on the enzyme(s) affected and the degree of quantitative or functional enzyme deficit. Withania somnifera (WS), commonly known as Ashwagandha, is a medicinal plant that has been employed for centuries in ayurvedic medicine. Preclinical studies have shown that WS increases circulating cortisol levels and improves insulin sensitivity. We report the case of a 57-year-old woman with non-classical adrenal hyperplasia due to both 3-β-ol dehydrogenase deficiency and aldosterone synthase deficiency who was self-treated with WS for 6 months. After 6 months of treatment her serum 18-OH-hydroxycorticoserone, 17-OH-pregnenolone, corticosterone and 11-deoxycortisol decreased by 31%, 66%, 69% and 55%, respectively. The biochemical improvement was accompanied by a noticeable reduction in scalp hair loss.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22987912      PMCID: PMC4543599          DOI: 10.1136/bcr-2012-006989

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  26 in total

1.  High frequency of nonclassical steroid 21-hydroxylase deficiency.

Authors:  P W Speiser; B Dupont; P Rubinstein; A Piazza; A Kastelan; M I New
Journal:  Am J Hum Genet       Date:  1985-07       Impact factor: 11.025

Review 2.  Extensive clinical experience: nonclassical 21-hydroxylase deficiency.

Authors:  Maria I New
Journal:  J Clin Endocrinol Metab       Date:  2006-08-15       Impact factor: 5.958

3.  Genotyping of CYP21, linked chromosome 6p markers, and a sex-specific gene in neonatal screening for congenital adrenal hyperplasia.

Authors:  J Fitness; N Dixit; D Webster; T Torresani; R Pergolizzi; P W Speiser; D J Day
Journal:  J Clin Endocrinol Metab       Date:  1999-03       Impact factor: 5.958

4.  Children with classic congenital adrenal hyperplasia have elevated serum leptin concentrations and insulin resistance: potential clinical implications.

Authors:  Evangelia Charmandari; Martina Weise; Stefan R Bornstein; Graeme Eisenhofer; Margaret F Keil; George P Chrousos; Deborah P Merke
Journal:  J Clin Endocrinol Metab       Date:  2002-05       Impact factor: 5.958

5.  Effect of Withania somnifera on insulin sensitivity in non-insulin-dependent diabetes mellitus rats.

Authors:  Tarique Anwer; Manju Sharma; Krishna Kolappa Pillai; Muzaffar Iqbal
Journal:  Basic Clin Pharmacol Toxicol       Date:  2008-03-16       Impact factor: 4.080

6.  Androgen excess in women: experience with over 1000 consecutive patients.

Authors:  R Azziz; L A Sanchez; E S Knochenhauer; C Moran; J Lazenby; K C Stephens; K Taylor; L R Boots
Journal:  J Clin Endocrinol Metab       Date:  2004-02       Impact factor: 5.958

7.  Microconversion between CYP21A2 and CYP21A1P promoter regions causes the nonclassical form of 21-hydroxylase deficiency.

Authors:  Rogério S Araújo; Berenice B Mendonca; Angela S Barbosa; Chin J Lin; José A M Marcondes; Ana Elisa C Billerbeck; Tânia A S S Bachega
Journal:  J Clin Endocrinol Metab       Date:  2007-07-31       Impact factor: 5.958

8.  Newly proposed hormonal criteria via genotypic proof for type II 3beta-hydroxysteroid dehydrogenase deficiency.

Authors:  Chantal Lutfallah; Weihua Wang; J Ian Mason; Ying Tai Chang; Anzar Haider; Barry Rich; Mariano Castro-Magana; Kenneth C Copeland; Raphael David; Songya Pang
Journal:  J Clin Endocrinol Metab       Date:  2002-06       Impact factor: 5.958

9.  Insulin insensitivity in adrenal hyperplasia due to nonclassical steroid 21-hydroxylase deficiency.

Authors:  P W Speiser; J Serrat; M I New; J M Gertner
Journal:  J Clin Endocrinol Metab       Date:  1992-12       Impact factor: 5.958

10.  Naturopathic care for anxiety: a randomized controlled trial ISRCTN78958974.

Authors:  Kieran Cooley; Orest Szczurko; Dan Perri; Edward J Mills; Bob Bernhardt; Qi Zhou; Dugald Seely
Journal:  PLoS One       Date:  2009-08-31       Impact factor: 3.240

View more
  2 in total

1.  Novel Methods to Generate Active Ingredients-Enriched Ashwagandha Leaves and Extracts.

Authors:  Sunil C Kaul; Yoshiyuki Ishida; Kazuya Tamura; Teruo Wada; Tomoko Iitsuka; Sukant Garg; Mijung Kim; Ran Gao; Shoichi Nakai; Youji Okamoto; Keiji Terao; Renu Wadhwa
Journal:  PLoS One       Date:  2016-12-09       Impact factor: 3.240

2.  Treatment of Nonclassic 11-Hydroxylase Deficiency with Ashwagandha Root.

Authors:  Daniel Powell; Taiga Inoue; Gül Bahtiyar; Gabriel Fenteany; Alan Sacerdote
Journal:  Case Rep Endocrinol       Date:  2017-06-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.